CRISPR Therapeutics AG
CRSPHealthcare|Biotechnology|Switzerland
$48.44
-0.71 (-1.44%)
Tangible Book
$20.04
Financials
Financial Snapshot
Market Cap
$4.65B
Enterprise Value
$1.77B
Revenue (TTM)
$0.00
Net Income (TTM)
$-581.6M
Cash & Equivalents
$1.98B
Net Cash/Share
$17.02
Free Cash Flow (TTM)
$-370.9M
Operating CF (TTM)
$-345.0M
Debt/Equity
0.11
Cash Runway & Burn Rate
Cash on Hand
$1.98B
Quarterly Burn
$86.3M
Monthly Burn
$28.8M
Est. Runway
~22.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $315.5M | $239.8M | $456.6M | $943.8M | $1.69B | $2.38B | $1.82B | $1.69B | $1.90B | $1.98B | $1.98B | |
| Operating Cash Flow | $-52.9M | $-70.1M | $-96.2M | $56.7M | $-238.4M | $539.0M | $-495.7M | $-260.4M | $-142.8M | $-345.0M | $-345.0M | |
| Free Cash Flow | $-55.9M | $-77.9M | $-99.0M | $50.0M | $-256.7M | $457.3M | $-532.9M | $-272.3M | $-144.7M | $-370.9M | $-370.9M | |
| Capital Expenditure | $-3.0M | $-7.8M | $-2.8M | $-6.7M | $-18.4M | $-81.7M | $-37.2M | $-12.0M | $-1.9M | $-25.9M | $-25.9M | |
| Financing Cash Flow | $183.2M | $2.6M | $315.9M | $431.0M | $1.02B | $250.9M | $38.6M | $62.7M | $332.0M | $426.0M | $426.0M |
R&D Spending
R&D (TTM)
$381.1M
R&D Intensity
—
R&D Growth YoY
+0.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $41.0M | $3.1M | $289.6M | $543.0K | $913.1M | $436.0K | $370.0M | $35.0M | $0.00 | $0.00 | |
| R&D Expense | $42.2M | $69.8M | $113.8M | $179.4M | $266.9M | $340.6M | $461.6M | $387.3M | $310.2M | $381.1M | $381.1M | |
| R&D % of Revenue | 817.9% | 170.3% | 3641.9% | 61.9% | 49161.3% | 37.3% | 105881.9% | 104.7% | 886.4% | — | — | |
| SG&A | $31.1M | $35.8M | $48.3M | $63.5M | $88.2M | $99.7M | $102.5M | $76.2M | $73.0M | $73.5M | $73.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $41.0M | $3.1M | $289.6M | $543.0K | $913.1M | $436.0K | $370.0M | $35.0M | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $101.2M | $110.3M | $130.3M | $120.7M | $213.5M | $213.5M | |
| Gross Profit | $5.2M | $41.0M | $3.1M | $289.6M | $543.0K | $811.9M | $-109.8M | $239.8M | $-85.7M | $-213.5M | $-213.5M | |
| R&D | $42.2M | $69.8M | $113.8M | $179.4M | $266.9M | $340.6M | $461.6M | $387.3M | $310.2M | $381.1M | $381.1M | |
| SG&A | $31.1M | $35.8M | $48.3M | $63.5M | $88.2M | $99.7M | $102.5M | $76.2M | $73.0M | $73.5M | $73.5M | |
| Operating Income | $-68.1M | $-64.6M | $-158.9M | $46.7M | $-354.4M | $373.5M | $-673.2M | $-222.5M | $-466.6M | $-664.6M | $-664.6M | |
| Interest Expense | $-8.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-22.7M | $-66.6M | $-164.4M | $67.3M | $-348.1M | $379.5M | $-650.5M | $-150.7M | $-362.7M | $-578.0M | $-578.0M | |
| Net Income | $-23.2M | $-68.4M | $-165.0M | $66.9M | $-348.9M | $377.7M | $-650.2M | $-153.6M | $-366.3M | $-581.6M | $-581.6M | |
| EPS (Diluted) | -1.89 | -1.71 | -3.44 | 1.17 | -5.29 | 4.70 | -8.36 | -1.94 | -4.34 | -6.47 | -6.52 | |
| EBITDA | $-13.7M | $-61.6M | $-155.4M | $51.5M | $-345.3M | $391.5M | $-649.0M | $-202.7M | $-447.3M | $-645.1M | $-645.1M | |
| Shares Out. (M) | 12.26 | 40.06 | 47.96 | 56.93 | 65.95 | 80.39 | 77.75 | 79.22 | 84.36 | 89.92 | 95.33 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $315.5M | $239.8M | $456.6M | $943.8M | $1.17B | $923.0M | $211.9M | $389.5M | $298.3M | $347.6M | $347.6M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $0.00 | $521.7M | $1.46B | $1.60B | $1.30B | $1.61B | $1.63B | $1.63B | |
| Total Current Assets | $320.2M | $248.4M | $466.4M | $987.5M | $1.72B | $2.42B | $1.85B | $1.91B | $1.94B | $1.99B | $1.99B | |
| Total Assets | $345.0M | $271.3M | $489.0M | $1.07B | $1.83B | $2.75B | $2.24B | $2.23B | $2.24B | $2.27B | $2.27B | |
| Total Current Liabilities | $22.0M | $14.5M | $27.7M | $57.1M | $94.3M | $119.9M | $121.1M | $108.8M | $87.8M | $149.1M | $149.1M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $112.1M | $83.5M | $96.8M | $127.3M | $163.7M | $352.4M | $367.6M | $346.8M | $310.0M | $343.4M | $343.4M | |
| Stockholders' Equity | $232.8M | $187.8M | $392.2M | $939.4M | $1.66B | $2.40B | $1.88B | $1.88B | $1.93B | $1.92B | $1.92B | |
| Retained Earnings | $-57.1M | $-125.4M | $-291.6M | $-224.7M | $-573.6M | $-195.9M | $-846.1M | $-999.7M | $-1.37B | $-1.95B | $-1.95B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-52.9M | $-70.1M | $-96.2M | $56.7M | $-238.4M | $539.0M | $-495.7M | $-260.4M | $-142.8M | $-345.0M | $-345.0M | |
| Capital Expenditure | $-3.0M | $-7.8M | $-2.8M | $-6.7M | $-18.4M | $-81.7M | $-37.2M | $-12.0M | $-1.9M | $-25.9M | $-25.9M | |
| Free Cash Flow | $-55.9M | $-77.9M | $-99.0M | $50.0M | $-256.7M | $457.3M | $-532.9M | $-272.3M | $-144.7M | $-370.9M | $-370.9M | |
| Investing Cash Flow | $31.9M | $-8.3M | $-2.8M | $1.3M | $-541.2M | $-1.04B | $-258.7M | $374.6M | $-280.5M | $-31.8M | $-31.8M | |
| Financing Cash Flow | $183.2M | $2.6M | $315.9M | $431.0M | $1.02B | $250.9M | $38.6M | $62.7M | $332.0M | $426.0M | $426.0M | |
| Issuance of Stock | $89.1M | $0.00 | $307.1M | $415.0M | $982.3M | $213.3M | $970.0K | $32.7M | $300.7M | $398.1M | $398.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $-57.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $35.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $10.8M | $18.9M | $35.0M | $44.1M | $66.0M | $102.4M | $97.9M | $81.0M | $86.6M | $72.5M | $72.5M | |
| Net Change in Cash | $162.0M | $-75.8M | $216.9M | $489.0M | $236.7M | $-245.5M | $-715.9M | $177.0M | $-91.3M | $49.3M | $49.3M |
Dilution Tracker
Shares Outstanding
95M
5-Year Share Growth
+18.6%
Stock Issuance (TTM)
$398.1M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 12.26 | 40.06 | 47.96 | 56.93 | 65.95 | 80.39 | 77.75 | 79.22 | 84.36 | 89.92 | 95.33 | |
| YoY Change % | — | 226.8% | 19.7% | 18.7% | 15.8% | 21.9% | -3.3% | 1.9% | 6.5% | 6.6% | 6.0% | |
| Stock Issuance | $89.1M | $0.00 | $307.1M | $415.0M | $982.3M | $213.3M | $970.0K | $32.7M | $300.7M | $398.1M | $398.1M | |
| Stock Repurchase | $0.00 | $0.00 | $-57.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $10.8M | $18.9M | $35.0M | $44.1M | $66.0M | $102.4M | $97.9M | $81.0M | $86.6M | $72.5M | $72.5M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 88.9% | -25186.7% | 64.8% | -244.8% | 0.0% | 0.0% | |
| Operating Margin % | -1319.3% | -157.7% | -5087.8% | 16.1% | -65273.5% | 40.9% | -154394.7% | -60.1% | -1333.0% | 0.0% | - | |
| Net Margin % | -449.3% | -166.7% | -5281.1% | 23.1% | -64247.7% | 41.4% | -149122.7% | -41.5% | -1046.4% | 0.0% | - | |
| EBITDA Margin % | -266.1% | -150.3% | -4975.2% | 17.8% | -63582.1% | 42.9% | -148850.7% | -54.8% | -1278.0% | 0.0% | - | |
| FCF Margin % | -1082.0% | -190.0% | -3169.4% | 17.3% | -47278.8% | 50.1% | -122231.4% | -73.6% | -413.4% | 0.0% | 0.0% | |
| ROE % | -22.8% | -32.5% | -56.9% | 10.0% | -26.8% | 18.6% | -30.4% | -8.2% | -19.2% | -30.2% | -31.2% | |
| ROA % | -9.2% | -22.2% | -43.4% | 8.6% | -24.1% | 16.5% | -26.0% | -6.9% | -16.4% | -25.8% | -26.6% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / 24.32 / 200.76
Industry Med.27.95
P/S—
Historical4.23 / 65.57 / 22208.89
Industry Med.9.84
P/B2.42
Historical1.54 / 3.15 / 12.26
Industry Med.2.92
EV/EBITDA-4.52
Historical-684.19 / -7.68 / 1665.17
Industry Med.12.92
EV/Revenue—
Historical1.88 / 46.44 / 23253.66
Industry Med.8.79
P/FCF—
Historical9.64 / 21.26 / 603.08
Industry Med.35.03
Intrinsic Value Models
Tangible Book
$20.04
Net Current Assets
$17.130
Net-Net Working Capital
$17.02
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | At Loss | At Loss | At Loss | 52.06 | At Loss | 16.12 | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | 48.12 | 22.95 | 439.54 | 11.97 | 19138.75 | 6.67 | 6775.00 | 13.40 | 94.84 | - | 0.00 | |
| PB Ratio | 3.46 | 5.07 | 3.78 | 3.94 | 6.80 | 2.43 | 1.70 | 2.66 | 1.75 | 2.62 | 2.42 | |
| EV/EBITDA | -35.60 | -11.58 | -6.59 | 54.62 | -28.06 | 9.40 | -2.50 | -17.54 | -3.79 | -5.05 | -4.52 | |
| EV/Revenue | 94.73 | 17.40 | 328.04 | 9.71 | 17842.03 | 4.03 | 3716.09 | 9.61 | 48.42 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $29.03M | $76.40M | $614.01M |
| Net Income | $-474.72M | $-427.85M | $-254.77M |
| EPS | -4.78 | -4.27 | -1.95 |
| Book Value per Share | 15.41 | 11.69 | 10.38 |
| Operating Cash Flow per Share | -3.10 | 1.00 | 4.41 |
| Operating CF | $-295.52M | $95.01M | $420.40M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Discovering, developing and commercializing therapies derived from or incorporating genome-editing | $3.5M |
By Geography
| Segment | 2025 |
|---|---|
| Switzerland | $3.5M |